For the active substances 1-naphthylacetamide, 1-naphthylacetic acid, 6-benzyladenine, aluminium sulfate, esfenvalerate, fluazifop-P, fluometuron, pinoxaden, prosulfuron, pyridaben, sintofen and spiroxamine, the risk assessment has not been finalised yet by the rapporteur Member State. Taking into account the subsequent steps to be completed in each renewal procedure, the duration of the extension of the approval periods of these active substances should be set at 42 months.
Recital 53, Regulation (EU) 2026/372
In forcesince 20 Feb 2026